Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors

• Published in: Nephrology (Carlton, Vic.) Vol. 26; no. 5; pp. 377 - 390
• Main Authors: Scholtes, Rosalie A., Baar, Michaël J. B., Kok, Megan D., Bjornstad, Petter, Cherney, David Z. I., Joles, Jaap A., Raalte, Daniël H.
• Format: Journal Article
• Language: English
• Published: Melbourne John Wiley & Sons Australia, Ltd 01.05.2021; Wiley Subscription Services, Inc
• Subjects: Angiotensin; Calcium; calcium channel blockers; Calcium Channel Blockers - pharmacology; Calcium Channel Blockers - therapeutic use; Cardiovascular diseases; Clinical trials; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - physiopathology; diabetic kidney disease; Diabetic Nephropathies - prevention & control; Diuretics; Diuretics - pharmacology; Diuretics - therapeutic use; Drug Interactions; Drugs; Glomerular filtration rate; Hemodynamics - drug effects; Humans; Kidney diseases; Morbidity; RAS inhibitors; Renal Circulation - drug effects; Renal function; renal haemodynamic function; Renin; Renin-Angiotensin System - drug effects; Review; Reviews; Risk factors; SGLT2 inhibition; Sodium-glucose cotransporter; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; type 2 diabetes humans; Vasodilation; diabetic kidney disease; renal haemodynamic function; RAS inhibitors; calcium channel blockers; diuretics; SGLT2 inhibition; type 2 diabetes humans

Diabetic kidney disease remains the leading cause of end‐stage kidney disease and a major risk factor for cardiovascular disease. Large cardiovascular outcome trials and dedicated kidney trials have shown that sodium‐glucose cotransporter (SGLT)2 inhibitors reduce cardiovascular morbidity and mortal...